MRNA - Moderna, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
-0.18 (-1.26%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close14.32
Bid0.00 x 1300
Ask0.00 x 900
Day's Range14.00 - 14.48
52 Week Range13.03 - 29.79
Avg. Volume1,278,441
Market Cap4.652B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • How Pinterest's IPO stacks up to other unicorns
    Yahoo Finance Video4 months ago

    How Pinterest's IPO stacks up to other unicorns

    Yahoo Finance's Zack Guzman and Heidi Chung are joined by Arthur Zaczkiewicz, Women’s Wear Daily executive editor, to discuss Pinterest's IPO.

  • Cramer: Investors can find a better entry point on these recent IPOs
    CNBC Videos4 months ago

    Cramer: Investors can find a better entry point on these recent IPOs

    Jim Cramer breaks down the action behind Yeti's recent moves.

  • 4 ‘Strong Buy’ Biotechs With Big 3Q19 Catalysts
    TipRanks17 hours ago

    4 ‘Strong Buy’ Biotechs With Big 3Q19 Catalysts

    Investing in biotech stocks can generate substantial returns. If data results meet key targets, or drug applications are accepted, share prices can soar. Unfortunately the reverse is also true. That means investors have to be particularly careful when it comes to biotech stocks. The following four stocks all show a Strong Buy Street consensus- based on ratings received over the last three months. They also boast significant upcoming catalysts this quarter- that could potentially send share prices soaring. Let’s take a closer look at each stock now: 1\. Intercept Pharmaceuticals (ICPT)Intercept Pharma is trying to help patients with progressive non-viral liver diseases. The company already has one drug on the market (for primary biliary cirrhosis), and recently released positive results from the Phase 3 REGENERATE trial in NASH Fibrosis. Nash is a chronic condition in which the buildup of fat and inflammation in the liver may eventually lead to severe scarring called fibrosis. It is currently the second leading cause of liver transplant in the US- making it a very lucrative opportunity for drug companies. Intercept has an early mover advantage here. The company plans to submit an NDA [new drug application] in 3Q19 and an MAA [marketing authorization application] in 4Q19. “Obeticholic Acid will likely be the first to market in NASH and is the only drug to have demonstrated a fibrosis benefit” cheers Needham analyst Alan Carr. “We acknowledge certain potential safety and tolerability limitations, but nevertheless expect the drug to have an important role in NASH therapy over the next several years” says the analyst. Overall the stock has a ‘Strong Buy’ Street consensus, with 5 recent buy ratings vs just 1 hold rating. Meanwhile the average analyst price target of $148 indicates huge upside potential of 113%. >>Click Here to see the full list of ICPT Analyst Ratings 2\. Rhythm Pharmaceuticals (RYTM)Rhythm is developing treatments for rare genetic deficiencies that result in life-threatening metabolic disorders. The big news here is that Rhythm is expected to announce results in 3Q19 from two Phase 3 trials of setmelanotide in POMC and LEPR Deficiency. There are currently no approved drugs for these diseases- and no other drugs in development.“We anticipate a positive outcome for both trials based on Phase 2 data demonstrating a profound and durable impact on appetite and weight” writes Carr. The analyst assumes US approval and launch in 4Q20 (EU 2021) and peak worldwide sales of around $265M in 2032.“Considering recent weakness, we believe the stock is attractive ahead of Phase 3 POMC and LEPR Deficiency trial results. We believe there is even more room for upside for the stock as the company completes label expansion trials in 2020+” enthuses Carr. Most notably label expansion Phase 3 trial in Bardet-Biedl/Alstrom Syndromes remains on track for results in 2H20. Success here adds another $485M in peak sales potential. “Additional patient populations under evaluation in a Phase 2 trial push peak sales above $1B” writes Carr. RYTM has four consecutive recent buy ratings from the Street, with an average price target of $40 (95% upside potential). >>Click Here to see the full list of RYTM Analyst Ratings 3\. Moderna Inc (MRNA)Moderna is hoping to create a new generation of transformative medicines for patients. The company’s approach is to use mRNA medicines to instruct a patient’s own cells to produce proteins that could prevent, treat, or cure disease. Encouragingly, all seven analysts covering MRNA rate the stock a buy- so no hold or sell ratings here. “We expect Moderna to provide updates on Cytomegalovirus (CMV), Chikungunya, and Methylmalonic Acidemia (MMA) programs by YE19” writes the analyst.While the commercial opportunity in Chikungunya is modest, he believes PK/PD data from the Phase 1 trial will provide valuable insight into the overall predictability of several other mRNA drugs in development at the company.“The stock has fallen substantially from its peak in May 2019. We believe there is an opportunity for upside in 2H19 as the company announces data from the above CMV, Chikungunya, and MMA programs” Carr concludes. Indeed, the Street’s $30 average price target suggests share prices can double in the coming months. >>Click Here to see the full list of MRNA Analyst Ratings 4\. Cara Therapeutics (CARA)Cara Therapeutics has surged 30% in last the three months. In May the company announced positive results from the first of two Phase 3 trials of IV Korsuva in Chronic Kidney Disease (CKD) dialysis patients with pruritus. Pruritus refers to the severe itching of the skin, a common and distressing symptom for patients with chronic kidney disease. Cara Therapeutics CEO Derek Chalmers noted at the time that the company was "particularly encouraged by the early [anti-itching] response with Korsuva injection." Now investors are keeping a close eye on results from the second trial (KALM-2) and from a Phase 2 trial of oral Korsuva in non-dialysis patients with CKD pruritus- both expected in 2H19. “We anticipate a positive outcome for both trials” comments Carr, adding that the recent results point to a favorable outcome for the KALM-2 trial. “We believe the outcome is also a positive indicator for the oral Korsuva programs in CKD pruritus, Liver Disease pruritus, and Atopic Dermatitis, all of which have large commercial opportunities.”Bottom line: “The stock is substantially undervalued.” All six analysts polled are bullish on CARA right now. Meanwhile the average analyst price target stands at $33 (30% upside potential). >>Click Here to see the full list of CARA Analyst RatingsDiscover the latest ratings from top analysts in any sector you choose

  • Here's Why Moderna Lost 29.6% in June
    Motley Fool8 days ago

    Here's Why Moderna Lost 29.6% in June

    The post-IPO blues hit pretty hard last month.

  • Options Traders Expect Huge Moves in Moderna (MRNA) Stock
    Zacks15 days ago

    Options Traders Expect Huge Moves in Moderna (MRNA) Stock

    Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.

  • Is Moderna, Inc. (MRNA) A Good Stock To Buy?
    Insider Monkey22 days ago

    Is Moderna, Inc. (MRNA) A Good Stock To Buy?

    It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]

  • Moderna, Inc. (NASDAQ:MRNA): Financial Strength Analysis
    Simply Wall St.last month

    Moderna, Inc. (NASDAQ:MRNA): Financial Strength Analysis

    Stocks with market capitalization between $2B and $10B, such as Moderna, Inc. (NASDAQ:MRNA) with a size of US$5.2b, do...

  • MIT gene-therapy spinout raises $6M, enters competitive mRNA field
    American City Business Journalslast month

    MIT gene-therapy spinout raises $6M, enters competitive mRNA field

    Strand Therapeutics hopes to create treatments using messenger RNA or mRNA, which gives instructions to the body’s cells to create proteins. But the young gene-therapy startup thinks it has created a better method than such players as Moderna Inc. and Translate Bio.

  • Preclinical biotech Stoke Therapeutics plans $86M IPO
    American City Business Journals2 months ago

    Preclinical biotech Stoke Therapeutics plans $86M IPO

    An RNA-altering startup led by some of the brains behind Biogen and Sarepta Therapeutics' blockbuster products is hoping to raise $86 million in an IPO, it disclosed Thursday.

  • In slow year for life science IPOs, this venture firm is making big money
    American City Business Journals2 months ago

    In slow year for life science IPOs, this venture firm is making big money

    The slowing of Massachusetts biotech and medical device companies’ stock market launches has left most venture creation firms without exit opportunities, except for one.

  • Moderna, Inc. (MRNA) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Moderna, Inc. (MRNA) Q1 2019 Earnings Call Transcript

    MRNA earnings call for the period ending March 31, 2019.

  • Why Earnings Season Could Be Great for Moderna (MRNA)
    Zacks2 months ago

    Why Earnings Season Could Be Great for Moderna (MRNA)

    Moderna (MRNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • 7 Strong Buy Stocks the Street Loves
    InvestorPlace3 months ago

    7 Strong Buy Stocks the Street Loves

    [Editor's note: This story was previously published in March 2019. It has since been updated and republished.]Which top stocks are Wall Street analysts the most bullish on? I mean stocks with no "hold" or "sell" ratings and a pure "strong buy" analyst consensus. These are the strong buy stocks that make the most compelling investing opportunities and are definitely worth keeping a close eye on.Using TipRanks powerful stock screener, I set out to pinpoint seven stocks that command the unanimous support of the Street. You can customize the screener settings to match your investment strategy. In this case, I selected filters for stocks of all market cap size with a "strong buy" consensus from analysts and best-performing analysts alike. These are the top analysts with the highest success rate and average return.InvestorPlace - Stock Market News, Stock Advice & Trading TipsHere I specifically select stocks with big upside potential from the current share price. This is based on the upside potential from the current share price to the average analyst price target. * 5 Dividend Stocks Perfect for Retirees Now let's delve into these seven top stocks to buy now:Source: Shutterstock Strong Buy Stocks: Exact Sciences (EXAS)Exact Sciences Corporation (NASDAQ:EXAS) has just received five back-to-back buy ratings from the Street. These "buys" flooded in following stellar Q4 earnings results. EXAS delivered a solid Q4 revenue beat and raised its 2019 revenue guidance to $710 million-$730 million, above its prior $700 million estimate. As it prepares to release its Q1 numbers April 30, those numbers still look achievable.Plus the future looks bright for sales for its Cologuard DNA test for colon cancer."EXAS is one of our top picks for 2019, and we reiterate our "buy" rating and our $100 PT," said five-star Canaccord Genuity analyst Mark Massaro. "Exact continues to execute at a high level and isn't afraid to make big investments to hit its ambitious goal of achieving $6 billion of revenue for Cologuard over time."That would give the company over 40% market share for its revolutionary screening product, first launched back in 2014.According to Massaro, even the new revenue guidance is beatable, writing "we see a path to upside to our raised estimates." A similar message comes from Baird's Catherine Ramsey. She writes: "We continue to see the potential for upside… and EXAS remains one of our top ideas."The average analyst price target right now stands at $104. Bear in mind shares have surged 45% year-to-date. Want to learn more about Exact Sciences? Get the free EXAS Stock Research Report.Source: Shutterstock OpenText (OTEX)Canadian cloud computing stock Open Text Corp (NASDAQ:OTEX) develops and sells enterprise information management (EIM) software. Essentially, this helps organizations safely manage and share business information.Since the company's inception in 1991, OpenText has deployed around $6 billion capital on acquisitions. Using these acquisitions, OTEX can cement its position as a leader in the EIM space."Our strategy is total growth," said CEO Mark Barrenechea said, "where M&A will continue to be our largest growth driver, augmented with organic growth." So far this strategy appears to be paying off. * 10 S&P 500 Stocks to Weather the Earnings Storm That level of optimism still is on Open Text's side as it prepares its May 1 report report on third-quarter earnings."We believe OpenText is likely to continue to create shareholder value through its acquisition strategy," RBC analyst Paul Treiber said following the encouraging Q2 numbers,Overall, five analysts have published recent bullish calls on the stock. That's with a $46.75 average price target -- 23% upside potential from the current share price. Shares are up 17% year-to-date. Get the OTEX Stock Research Report.Source: Shutterstock Moderna (MRNA)Moderna (NASDAQ:MRNA) is a pioneer in a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching. No less than eight analysts have published recent buy ratings on the stock.Right now the company just reported positive results from an ongoing phase Ib trial. This is for mRNA-1653, an mRNA-based vaccine for the treatment of human metapneumovirus (HMPV) and parainfluenza virus (PIV3)."The interim phase I data announced today support our outlook for this experimental product and support advancing studies in the pediatric population" said Oppenheimer's Leah R Cann.The mRNA-1653 program is one of Moderna's 21 most current and importantly, one of its 13 focus programs.She points out that currently there are no approved vaccines to prevent hMPV or PIV3 infections, and estimates that worldwide mRNA-1653 sales could reach $1.44 billion by 2030. That's with a predicted launch date of 2024.With a $27 price target, Cann sees upside potential of 19% for the coming months. Shares are currently surging more than 45% in 2019. Get the MRNA Stock Research Report.Source: via Flickr (modified) Nexstar Media (NXST)Following its completion of the Media General acquisition, Nexstar Media Group (NASDAQ:NXST) owns 171 television stations. As the largest TV station operator in the U.S. reaching nearly 39% of households, Nexstar Media Group is a stock worth watching.Analysts certainly seem to think so. Nexstar has received six recent buy calls from the Street. Most notably, Evercore ISI's David Joyce upgraded NXST from "hold" to "buy" back in December. As a result, Nextar Media stock now scores unanimous support.Crucially, the company is on the verge of a fresh acquisition. It has agreed a $6.4 billion deal to buy Tribune's ABC, CBS, FOX, and NBC stations. Tribune shareholders recently approved the deal. What's more, to help avoid any anti-trust issues, Nexstar has announced that it would sell 14 stations. * 7 Marijuana Companies: Which Pot Stocks Should You Buy? "We assign Nexstar an Outperform rating and a $112 price target. We believe that the Tribune acquisition should create significant value for shareholders," top RBC Capital analyst Leo Kulp tells investors.He ramped up his price target from $96 to $112 (23% upside potential) adding, "We see limited risk around regulatory approvals…We expect the FCF yield to moderate as the company completes the milestones to closing the deal and de-levers post-closing." Get the NXST Stock Research Report.Source: Ace Via on Flickr Boyd Gaming (BYD)Shares in Boyd Gaming Corp (NYSE:BYD) have exploded by 11% in just five days. That's thanks to a pretty exceptional earnings report for the Paradise, Nevada-based casino company."BYD's 4Q18 operating results were nothing short of sensational," said five-star Stifel Nicolaus analyst Steven Wieczynski. "As we get late into EPS season, we believe we have seen the best print to date, with BYD's strong 4Q18 results tonight, an exclamation point on a strong 2018, with guidance above expectations serving as the cherry on top."With widespread growth throughout the business, BYD EBITDAR came in at $208.6mm, easily surpassing the estimated $197.1 million. Meanwhile 2019 EBITDAR guidance was established at a healthy $885 million-910 million, the midpoint of which was above Consensus forecasts ahead of the print ($888 million)."Post the strong 4Q18 results and with, we believe BYD is well positioned to continue to show healthy and steady same-store growth, while continuing to integrate its accretive acquisitions from the 2H18," said Deutsche Bank's Carlo Santarelli.That's with a "very compelling" current valuation to boot. With a "strong buy" analyst consensus, BYD boasts five recent buy ratings and a $37.80 average price target (22% upside potential). Get the BYD Stock Research Report.Source: Shutterstock LivePerson (LPSN)As the name suggests, LivePerson (NASDAQ:LPSN) provides online real-time assistance and expert advice. The cloud-based chat company has just hit all-time highs following its strongest revenue growth in three years. For the third time in a row, LPSN reported 14% quarterly revenue growth. Shares are now up 50% year-to-date.Even if the company can't keep up the pace when it reports earnings May 2, it still is a keeper.Going forward, analysts are firmly bullish about LivePerson's outlook. Seven analysts have published recent buy ratings on the stock, including (five-star Oppenheimer analyst Koji Ikeda. * 7 AI Stocks to Watch with Strong Long-Term Narratives "We believe LivePerson is well positioned to take share in a large B2C messaging opportunity that is disrupting the contact center" writes Ikeda. "Organizations around the world are under pressure to rethink and retool legacy technologies with next-generation customer engagement applications, like LivePerson, to better engage, retain, and generate revenue from the end-consumer" the analyst explains.He believes that over time, good execution in quarterly results and improving business fundamentals should narrow the valuation gap between LPSN and the SaaS Industry average. That makes it a great strong buy stock. Get the LPSN Stock Research Report.Source: Shutterstock Cubic Corp (CUB)Despite Brexit concerns and increasing volatility, Growth remains par for the course for Irish defense contractor Cubic Corp (NYSE:CUB).The company has three key business divisions. For investors, it is the company's flagship Cubic Transportation Systems unit that is worth keeping an eye on. According to the company, this is the division responsible for "automated fare payment, traffic management and enforcement solutions."Indeed, transport systems revenue was up 24% year over year, according to CUB's most recent earnings report. Consequently, Citigroup's Jonathan Raviv cited recent wins- especially in transport- as behind his bullish take on the stock.Meanwhile, Drexel Hamilton's David Williams writes: "We remain positive on CUB and expect further acquisitions to supplement top and bottom-line growth, which is likely to drive short term upside to expectations, and provide a strong long-term growth trajectory."As such, the analyst reiterates his "buy" rating and $85 price target (38% upside potential) on this strong buy stock. Six analysts give the stock a buy rating, while their average price target works out at $76.80. Get the CUB Stock Research offers exclusive insights for investors by focusing on the moves of experts: Analysts, Insiders, Bloggers, Hedge Fund Managers and more. See what the experts are saying about your stocks now at As of this writing, Harriet Lefton did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Reasons Kraft Heinz Stock Is a Contrarian Buy * 5 Housing Stocks to Buy for Renewed Homebuilder Confidence * 7 of the Best ETFs to Buy for a Rock-Solid Portfolio Compare Brokers The post 7 Strong Buy Stocks the Street Loves appeared first on InvestorPlace.

  • 4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics
    Zacks3 months ago

    4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics

    We take a look at companies, which have been developing treatments for various diseases using RNAi technology.

  • 3 Biotech Stocks That Doubled After Hitting Bottom in 2018
    Motley Fool3 months ago

    3 Biotech Stocks That Doubled After Hitting Bottom in 2018

    Find out how shares of these biopharmaceutical companies outperformed for some lucky investors with great timing.

  • CNBC3 months ago

    Cramer's lightning round: I promised my kids I wouldn't, but I recommend this stock

    Jim Cramer zips through his thoughts on callers' questions about their stock picks of the day.

  • Why The Biggest IPO In Biotech History Could Have A 'Disruptive' Impact
    Investor's Business Daily3 months ago

    Why The Biggest IPO In Biotech History Could Have A 'Disruptive' Impact

    Moderna stock popped Friday after an analyst rated it a buy, saying the biotech could launch a "disruptive class of medicines." Moderna is experimenting with messenger RNA in several areas.

  • Benzinga4 months ago

    Jim Cramer Gives His Opinion On Bristol-Myers Squibb, Moderna And More

    On CNBC's "Mad Money Lightning Round,"  Jim Cramer said he likes Moderna Inc (NASDAQ: MRNA ). He thinks that its technology is good and he believes it's going to be hard pressed to be independent. ...

  • Cambridge VC Flagship raises $824M for new life science investments
    American City Business Journals4 months ago

    Cambridge VC Flagship raises $824M for new life science investments

    One of Massachusetts’ largest venture capital firms, Flagship Pioneering, has raised $824 million to fund new life science startups, it announced Wednesday.

  • GuruFocus.com4 months ago

    Moderna Inc (MRNA) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Moderna Inc (NASDAQ:MRNA) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.

  • How Much Of Moderna, Inc. (NASDAQ:MRNA) Do Insiders Own?
    Simply Wall St.4 months ago

    How Much Of Moderna, Inc. (NASDAQ:MRNA) Do Insiders Own?

    If you want to know who really controls Moderna, Inc. (NASDAQ:MRNA), then you'll have to look at the makeup of its share registry. Large companies usually have institutions as shareholders,Read More...

  • Andreas Halvorsen's 5 Largest Stock Buys in 4th Quarter
    GuruFocus.com5 months ago

    Andreas Halvorsen's 5 Largest Stock Buys in 4th Quarter

    Viking Global rearranges portfolio at end of losing year, expands tech holdings